Zoetis Study Shows Simparica Trio Outperforms NexGard Plus Against Drug-Resistant Heartworm

  • Zoetis' Simparica Trio protected 3x more dogs from infection with a resistant heartworm isolate than NexGard Plus in a head-to-head study.
  • The study, published in Parasites & Vectors, involved 24 dogs experimentally challenged with the ML-resistant Dirofilaria immitis ZoeLA isolate.
  • Simparica Trio delivered a higher moxidectin dosage (24 µg/kg) compared to NexGard Plus (12 µg/kg), resulting in significantly lower heartworm counts.
  • No Simparica Trio-treated dogs had detectable microfilariae at the study's end, compared to 13% of NexGard Plus-treated dogs.

The study underscores the growing challenge of drug-resistant heartworm, a trend that threatens the efficacy of existing preventives. Zoetis' higher-dosage formulation of moxidectin in Simparica Trio could set a new standard for heartworm prevention, particularly in regions where resistance is emerging. The findings may also pressure competitors to adjust their formulations or dosing strategies.

Market Differentiation
How Zoetis will leverage these findings to position Simparica Trio against NexGard Plus in regions with drug-resistant heartworm.
Regulatory Impact
Whether the study results will influence veterinary guidelines for heartworm prevention in areas with resistant isolates.
Product Adoption
The pace at which veterinarians and pet owners shift to higher-dosage moxidectin preventives like Simparica Trio.